Phase I program will evaluate an affinity-tunable antibody-drug conjugate for high-grade serous ovarian cancer LOS ANGELES, CA — September 10, 2026 — Mabswitch Inc (Mabswitch) today announced that it has received a Small Business Innovation Research (SBIR) Phase I award from the National Cancer Institute (NCI), part of the National Read more
At a Pitch Day competition in Los Angeles hosted by GeneOnline US in collaboration with the Taiwan Biomedical Innovation Association (TiBIA), aimed at discovering transformative start-ups that could revolutionize the field, Mabswitch Inc. was awarded the “Best Breakthrough Award“. The event showcased breakthrough discoveries and partnerships in biotechnology and offered Read more
Barcelona, March 19, 2024 – Mabswitch was selected out of several biotech start-up companies to be part of the 8 finalists pitching at the StartUP Spotlight taking place during BIO Europe Spring 2024 in Barcelona, and emerged as the winner of the competition. The proud winner, Mabswitch Co-founder & CEO, Read more
Los Angeles, CA – Mabswitch Inc, a pioneering biotechnology company at the forefront of cutting-edge bioprocess technologies, is proud to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 grant by the National Center for Advancing Translational Sciences (NCATS), a center of the National Institutes Read more
Los Angeles, CA – Mabswitch Inc, a pioneering biotechnology company at the forefront of cutting-edge cancer immunotherapies, is proud to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 grant by the National Cancer Institute (NCI). This grant will support Mabswitch’s groundbreaking project, titled “SaefCAR: Read more
Mabswitch was awarded the Bristol Myers Squibb Golden Ticket. The award provides one year of fully paid individual laboratory bench space and membership at BioLabs@NYULangone, a fully equipped, laboratory-based incubator in Manhattan with facilities, support and equipment designed to accelerate early-stage startups in the life sciences and biopharma spaces. Mabswitch Read more
The MBC BioLabs Diversity Golden Ticket supported by AbbVie award provides lab space fitted with state-of-the-art research equipment, professional support staff, conference room space for meetings, and a vibrant, collaborative community to share ideas and expertise with other exciting life science companies. The Golden Ticket is awarded to early-stage companies Read more
MabSwitch™ is an awardee of the 2021 Inspire QuickFire Challenge for Diverse Innovators for its approach to create innovative solutions for patients. The Inspire QuickFire Challenge is a joint program of California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, AbbVie, 5AM Ventures, and Johnson & Johnson Read more